Last edition
News about
This agreement is the second such agreement in as many months shows TCBP's commitment to its M&A strategy aimed at expanding its therapeutic platform.
Vesica Health Announces Launch of AssureMDx Test to Improve Bladder Cancer Detection
VESICA HEALTH, INC., a multi-omics liquid biopsy company dedicated to improving the management of hematuria patients and the early detection of bladder cancer, announced the launch of its laboratory-developed AssureMDx™ test.
Inspira Technologies Commences Production of INSPIRA ART100 Medical Device
This manufacturing partner has initiated the production and assembly process for the first batch of INSPIRA ART100 devices.
This approval provides an alternative administration option for individuals experiencing dysphagia or difficulty swallowing.
RaySearch Join Forces with C-RAD to Enhance Quality of Radiation Therapy
RaySearch Laboratories has signed a collaboration deal with C-RAD, aimed at developing innovative solutions and products to enhance the quality of radiation therapy.
Lupin Introduces Rymti Biosimilar Etanercept in Canada
Lupin Ltd. has developed Rymti, Lupin’s first biosimilar in Canada, through its partner Sandoz Canada (Sandoz).
Bespak Partners with H and T Presspart to Boost Transition to Low GWP Propellants in pMDIs
Bespak has teamed up with H&T Presspart to accelerate the industry’s transition from existing pressurised Metered Dose Inhaler (pMDI) formulations to more climate-friendly alternatives utilising low global warming potential (GWP) propellants.
Novartis to Acquire Mariana Oncology to Expand RLT Pipeline
Novartis has decided to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient needs.
SonoVascular Partners with Lantheus for Innovative Treatment of Venous Thromboembolism
The collaboration aims to utilize Lantheus' microbubbles in conjunction with SonoVascular's innovative SonoThrombectomy System to treat deep vein thrombosis (DVT) and pulmonary embolism (PE).
Sentynl Therapeutics Completes Acquisition of Eiger BioPharmaceuticals' Zokinvy Program
Zokinvy is the first and only treatment approved by the US Food and Drug Administration (FDA) for Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy